Log In
Print this Print this

levetiracetam (AGB101)

  Manage Alerts
Collapse Summary General Information
Company AgeneBio Inc.
DescriptionLow-dose formulation of levetiracetam, a high affinity synaptic vesicle protein (SV2A) ligand
Molecular Target Synaptic vesicle protein (SV2A)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationCognitive dysfunction
Indication DetailsTreat amnestic mild cognitive impairment (aMCI)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today